Business Description
Lyell Immunopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US55083R2031
Share Class Description:
LYEL: Ordinary SharesTotal Employee Number:
161Description
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.43 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.22 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -5.63 | |||||
Beneish M-Score | -3.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -93.4 | |||||
3-Year EBITDA Growth Rate | 6.7 | |||||
3-Year EPS without NRI Growth Rate | 5.6 | |||||
3-Year FCF Growth Rate | 17.5 | |||||
3-Year Book Growth Rate | -44.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.53 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 1655.94 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.64 | |||||
9-Day RSI | 43.63 | |||||
14-Day RSI | 44.63 | |||||
3-1 Month Momentum % | -46.71 | |||||
6-1 Month Momentum % | -47.18 | |||||
12-1 Month Momentum % | 34.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.23 | |||||
Quick Ratio | 7.23 | |||||
Cash Ratio | 6.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.4 | |||||
Shareholder Yield % | -13.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -608138.71 | |||||
Net Margin % | -794858.07 | |||||
EBITDA Margin % | -574493.55 | |||||
FCF Margin % | -433609.68 | |||||
OCF Margin % | -431600 | |||||
ROE % | -82.89 | |||||
ROA % | -64.37 | |||||
ROIC % | -191.83 | |||||
3-Year ROIIC % | 6.99 | |||||
ROC (Joel Greenblatt) % | -326.55 | |||||
ROCE % | -54.88 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6555 | |||||
PB Ratio | 1.12 | |||||
Price-to-Tangible-Book | 1.12 | |||||
EV-to-EBIT | -0.57 | |||||
EV-to-EBITDA | -0.6 | |||||
EV-to-Revenue | 3442.42 | |||||
EV-to-Forward-Revenue | 51030.15 | |||||
EV-to-FCF | -0.79 | |||||
Price-to-GF-Value | 2.51 | |||||
| Price-to-Net-Current-Asset-Value | 1.62 | |||||
| Price-to-Net-Cash | 1.74 | |||||
Earnings Yield (Greenblatt) % | -175.44 | |||||
FCF Yield % | -41.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LYEL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lyell Immunopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.031 | ||
| EPS (TTM) ($) | -12.742 | ||
| Beta | 2.0054 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.37 | ||
| Volatility % | 86.4 | ||
| 14-Day RSI | 44.63 | ||
| 14-Day ATR ($) | 1.229873 | ||
| 20-Day SMA ($) | 13.7215 | ||
| 12-1 Month Momentum % | 34.25 | ||
| 52-Week Range ($) | 9.28 - 45 | ||
| Shares Outstanding (Mil) | 24.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lyell Immunopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lyell Immunopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 113 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 21 days | ||
| H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | 2026-06-30 13:30 | 12.75 (+7.69%) | ||
| General meeting for 2026 | 2026-06-10 08:00 | 12.70 (+1.60%) | ||
| Guidance call for 2026 | 2026-06-08 11:20 | 11.97 (-7.85%) | ||
| Guidance call for 2026 | 2026-05-20 16:00 | 16.13 (+0.81%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 11:00 | 16.51 (-7.66%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 20.62 (-1.90%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-14 11:00 | 24.80 (+9.25%) | ||
| Annual report for 2025 | 2026-03-12 | 25.14 (-2.75%) |
Show
Entries
Lyell Immunopharma Inc Frequently Asked Questions
What is Lyell Immunopharma Inc(LYEL)'s stock price today?
The current price of LYEL is $13.19. The 52 week high of LYEL is $45.00 and 52 week low is $9.28.
When is next earnings date of Lyell Immunopharma Inc(LYEL)?
The next earnings date of Lyell Immunopharma Inc(LYEL) is 2026-08-12 Est..
Does Lyell Immunopharma Inc(LYEL) pay dividends? If so, how much?
Lyell Immunopharma Inc(LYEL) does not pay dividend.
Guru Commentaries on NAS:LYEL
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform | 2023-09-11 |
Articles on Lyell Immunopharma Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers